Payment overview · 2025
General Payments
$11,189.83
180 reported records · 39 companies
Healthcare provider profile · identity verified
Daniel Lamar Cobb, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · GAINESVILLE, GA · NPI 1457568644
Verified facts
What the public records show
CMS Open Payments records show Daniel Lamar Cobb, MD received $11,189.83 in general payments during 2025 across 180 reported records.
ABBVIE INC. accounted for 64.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Fycompa, Gamunex-C, Hizentra, Nuplazid, Qulipta, Ubrelvy, Wakix, Xywav.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rytary by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Fycompa by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Hizentra by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Gamunex-C by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wakix by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xywav by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $7,233.12 | 64.6% | 28 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $365.52 | 3.3% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $337.09 | 3.0% | 19 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $221.42 | 2.0% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $205.50 | 1.8% | 11 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$182.10 | 1.6% | 6 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $181.44 | 1.6% | 5 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $171.25 | 1.5% | 6 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $166.72 | 1.5% | 6 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $162.65 | 1.4% | 1 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $136.91 | 1.2% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $134.27 | 1.2% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $123.71 | 1.1% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $117.97 | 1.1% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $116.82 | 1.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $114.54 | 1.0% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $113.40 | 1.0% | 5 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $95.34 | 0.8% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $89.51 | 0.8% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $88.23 | 0.8% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $86.14 | 0.8% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $79.14 | 0.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.75 | 0.7% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.58 | 0.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.77 | 0.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.80 | 0.5% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $46.49 | 0.4% | 3 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $45.94 | 0.4% | 2 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $45.24 | 0.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.38 | 0.4% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.63 | 0.3% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.79 | 0.3% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.30 | 0.3% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $27.17 | 0.2% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$25.33 | 0.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.21 | 0.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.58 | 0.2% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $19.39 | 0.2% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $16.69 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,825.00 | 4 |
| Food and Beverage | $4,082.06 | 172 |
| Education | $223.97 | 3 |
| Travel and Lodging | $58.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $6,934.04 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $255.96 | 18 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $205.50 | 11 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $194.06 | 10 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $190.76 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $185.59 | 13 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $162.65 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $151.50 | 6 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $147.50 | 6 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $144.43 | 6 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $136.91 | 5 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $124.00 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $123.71 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $117.97 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $116.82 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $114.54 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.02 | 10 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $102.84 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $95.34 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $89.51 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $88.23 | 3 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $86.14 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $82.10 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $79.14 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $77.16 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $67.58 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $63.77 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $60.81 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $56.80 | 3 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $49.76 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $48.06 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $46.49 | 3 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $45.94 | 2 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $38.10 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $37.85 | 2 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $33.63 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| GALLANT Normalized: gallant |
Device | Abbott Laboratories | $30.70 | 1 | 2025 |
Source payment records
|
|||||
| DEFITELIO Normalized: defitelio |
Drug | JAZZ PHARMACEUTICALS INC. | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $29.30 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $28.55 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $25.33 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.21 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $16.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 225 | exact normalized | Medicare Part D |
| Hizentra hizentra |
2025 | Hizentra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XYWAV xywav |
2025 | Xywav | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
225 | 18 |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | XYWAV open payments reported associated product |
CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700 |
Xywav · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 369 | 144 |
| Donepezil Hcl | Donepezil Hcl | 237 | 83 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 229 | 79 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 225 | 18 |
| Primidone | Primidone | 159 | 57 |
| Memantine Hcl | Memantine Hcl | 130 | 40 |
| Clonazepam | Clonazepam | 120 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 34 |
| Levetiracetam | Levetiracetam | 118 | 35 |
| Topiramate | Topiramate | 111 | 31 |
| Memantine Hcl Er | Memantine Hcl | 102 | 24 |
| Pregabalin | Pregabalin | 102 | 40 |
| Galantamine Hbr | Galantamine Hbr | 85 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 66 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 20 |
| Lamotrigine | Lamotrigine | 54 | 13 |
| Tramadol Hcl | Tramadol Hcl | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 17 |
| Nuplazid | Pimavanserin Tartrate | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 12 |
| Rytary | Carbidopa/Levodopa | 43 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 40 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | suppressed |
| Neupro | Rotigotine | 35 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Entacapone | Entacapone | 34 | suppressed |
| Eszopiclone | Eszopiclone | 34 | 14 |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 31 | 12 |
| Carbamazepine Er | Carbamazepine | 30 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | 12 |
| Amantadine | Amantadine Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Zaleplon | Zaleplon | 28 | 12 |
| Botox | Onabotulinumtoxina | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | 12 |
| Armodafinil | Armodafinil | 25 | suppressed |
| Fycompa | Perampanel | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Qulipta | Atogepant | 23 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Wakix | Pitolisant Hcl | 20 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Nourianz | Istradefylline | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Ubrelvy | Ubrogepant | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Levetiracetam Er | Levetiracetam | 14 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Xywav | Sodium,calcium,mag,pot Oxybate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $11,189.83 · 180 records | ABBVIE INC. | AMYVID, AUSTEDO XR, AVEIR, Albuked, BOTOX, BRIUMVI, Briviact, CARTO 3, CREXONT, DEFITELIO, ELYXYB - CELECOXIB, EPIDIOLEX, Exablate, FYCOMPA, Fintepla, GALLANT, GAMMAKED, GOMEKLI, Gamunex-C, HYQVIA, Hizentra, INGREZZA, KEDRAB, KESIMPTA, KISUNLA, KOATE, LEQEMBI, LUMRYZ, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PRECIVITYAD2, PURIFIED CORTROPHIN GEL, QULIPTA, REXULTI, RhoGAM Ultra-Filtered PLUS, Rystiggo, Senza, Sunosi, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, XYWAV, ZEPOSIA, ZTLido, Zilbrysq | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error